34 results on '"Verri, Carla"'
Search Results
2. Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening–Detected Lung Cancers
3. Supplementary Tables from Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study
4. Figure S1 from Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study
5. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer
6. Elevated levels of the acute-phase serum amyloid are associated with heightened lung cancer risk
7. Fragile Histidine Triad Gene Inactivation in Lung Cancer: The European Early Lung Cancer Project
8. Plasma DNA Quantification in Lung Cancer Computed Tomography Screening: Five-Year Results of a Prospective Study
9. Correction: Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening
10. A plasma miRNA signature classifier identifies PD-L1 ≥ 50% NSCLC nonresponders to immune checkpoint inhibitors.
11. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study
12. Circulating mir‐320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk
13. Complement C4d-specific antibodies for the diagnosis of lung cancer
14. MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
15. Abstract 2753: Mutational profiles from targeted NGS combine with miRNA-based liquid biopsy to predict survival in LDCT screening-detected lung cancers
16. OA06.02 Mutational Load Predicts Survival in LDCT Screening-Detected Lung Cancers
17. P2.01-017 Circulating miRNAs in Lung Cancer Are Associated to Pro-Tumorigenic and Immunosuppressive Microenvironment
18. Abstract 948: Microenvironmental origin of circulating miRNAs in lung cancer
19. MicroRNA Profile of Lung Tumor Tissues Is Associated with a High Risk Plasma miRNA Signature
20. Therapeutic Use of MicroRNAs in Lung Cancer
21. Novel method to detect microRNAs using chip-based QuantStudio 3D digital PCR
22. Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening
23. Abstract 932: A plasma microRNAs test predicts prognosis and disease status at follow-up in screening-detected lung cancer patients
24. Recent advances of microRNA-based molecular diagnostics to reduce false-positive lung cancer imaging
25. Abstract 871: Clinical utility of a plasma microRNA biomarker within lung cancer screening
26. YAP1acts as oncogenic target of 11q22 amplification in multiple cancer subtypes
27. Assessment of Circulating microRNAs in Plasma of Lung Cancer Patients
28. Clinical Utility of a Plasma-Based miRNA Signature Classifier Within Computed Tomography Lung Cancer Screening: A Correlative MILD Trial Study
29. Abstract A19: Origin and functional role of plasma circulating miRNAs.
30. Abstract IA22: miRNA and lung cancer: Early detection in high-risk subjects
31. Abstract 1162: MicroRNA expression profiles of tumors, normal lung tissues and plasma samples from spiral-computed tomography (CT) trial for early lung cancer detection
32. Plasma DNA levels in spiral CT-detected and clinically detected lung cancer patients: A validation analysis
33. Circulating miRNAs in Lung Cancer Are Associated to Pro-Tumorigenic and Immunosuppressive Microenvironment
34. YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.